SUBSCRIBE

Lundbeck US Response to COVID-19
News Releases
Lundbeck US Response to COVID-19
Update on the measures we have in place to preserve the health of our communities during this time.

ABOUT THE NEWSROOM

Here you will find media contacts, plus the latest news, stories and insights from Lundbeck US. Lundbeck is a global pharmaceutical company solely focused on the brain, and our 900+ U.S. employees are committed to improving the lives of people affected by psychiatric and neurological disorders.

Science
Science
Perspective
PERSPECTIVES
our-impact
Our Impact
press-release
News Releases
VYEPTI™ (eptinezumab-jjmr) Demonstrated Significant Positive Impact in Prevention of Chronic Migraine in Adults, Pivotal Phase III Study Published in Neurology Finds
News Releases
VYEPTI™ (eptinezumab-jjmr) Demonstrated Significant Positive Impact in Prevention of Chronic Migraine in Adults, Pivotal Phase III Study Published in Neurology Finds
Looking Out for the Invisibly Vulnerable in the Time of COVID-19
Perspectives
Looking Out for the Invisibly Vulnerable in the Time of COVID-19
By Doug Williamson, MD
Video: The Evolution of Migraine Care & Treatment
Science
Video: The Evolution of Migraine Care & Treatment
Lundbeck receives grant from The Michael J. Fox Foundation for Parkinson’s disease research
News Releases
Lundbeck receives grant from The Michael J. Fox Foundation for Parkinson’s disease research
Together We’re Stronger: Lundbeck’s Big-Tent Approach to Patient Advocacy
Our Impact
Together We’re Stronger: Lundbeck’s Big-Tent Approach to Patient Advocacy

This site contains medical information that is intended for residents of the United States only and is not meant to substitute for the advice provided by a medical professional. Always consult a physician if you have health concerns. Use and access of this site are subject to the terms and conditions as set out in our Privacy Policy and Terms of Use. 

© Copyright 2018 Lundbeck. All rights reserved.